Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pilot Study of Perindopril in Childhood Cancer Survivors
NCT01948232 · The Hospital for Sick Children · PHASE2 · withdrawn · last registry update 2015-10-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “no participants enrolled” | – | Registry record, The Hospital for Sick Children |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ACE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-09-14Phase 3 first posted: Novartis Pharmaceuticals, LCZ696 (Sacubitril/Valsartan) + Placebo of LCZ696 (Sacubitril/Valsartan) (NCT02900378)
- 2016-08-15Also stopped (terminated): Novartis Pharmaceuticals, LCZ696 200 mg BID + Enalapril 10 mg BID (NCT01035255)
- 2016-06-28Also stopped (terminated): Meir Medical Center, Lercanidipine/enalapril fixed combination (NCT01211314)
- 2016-04-13Phase 3 first posted: UMC Utrecht, Ceftriaxone + Macrolide + Moxifloxacin or Levofloxacin (NCT02735707)
- 2016-04-06Phase 3 first posted: Sunnybrook Health Sciences Centre, ramipril + perindopril (NCT02729441)
- 2016-04-05Also stopped (terminated): Nanfang Hospital, Southern Medical University, Benazepril + Losartan (NCT00630708)
- 2016-03-07Results posted on the registry: Novartis Pharmaceuticals, Aliskiren + Enalapril (NCT01151410)
- 2016-02-24Also stopped (terminated): Institut National de la Santé Et de la Recherche Médicale, France, perindopril + placebo (NCT01583114)
- 2016-02-09Phase 3 first posted: Novartis Pharmaceuticals, LCZ696 + Enalapril (NCT02678312)
- 2016-01-20Also stopped (withdrawn): Shenzhen Ausa Pharmed Co.,Ltd, Enalapril maleate and folic acid tablets + Enalapril maleate (NCT01871740)
- 2016-01-13Phase 3 first posted: Ethicare GmbH, Enalapril Orodispersible Minitablet (NCT02654678)
- 2016-01-12Phase 3 first posted: Ethicare GmbH, Enalapril Orodispersible Minitablet (NCT02652741)
- 2016-01-12Phase 3 first posted: Ethicare GmbH, Enalapril Orodispersible Minitablet (NCT02652728)
- 2015-12-18Results posted on the registry: The Hospital for Sick Children, Enalaprilat (NCT00741156)
- 2015-11-11Results posted on the registry: Hospital Universitario Pedro Ernesto, Benazepril + Losartan (NCT01603940)
- 2015-11-04Results posted on the registry: Vanderbilt University, Sitagliptin (DPP4 inhibitor) + Substance P, (NCT01413542)
- 2015-10-14Phase 3 first posted: Fuling Central Hospital of Chongqing City, Enalapril Maleate Tablets(as the program-based antihypertension) + Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension) (NCT02575092)
- 2015-09-07Results posted on the registry: Novartis Pharmaceuticals, LCZ696 200 mg BID + Enalapril 10 mg BID (NCT01035255)
- 2015-08-25Results posted on the registry: Symplmed Pharmaceuticals LLC, XOMA 985 + Amlodipine Besylate (NCT01556997)
- 2015-06-10Phase 3 first posted: Novartis Pharmaceuticals, LCZ696 + Enalapril (NCT02468232)
- 2015-06-09Also stopped (terminated): St George's, University of London, Enalapril 20 mg bd + Candesartan 8 mg bd (NCT00141583)
- 2015-06-03Also stopped (withdrawn): Monash University, Perindopril + Perindopril/amlodipine (NCT01089452)
- 2015-05-04Phase 3 first posted: InCor Heart Institute, Enalapril (NCT02432885)
- 2014-12-15Results posted on the registry: Wake Forest University Health Sciences, lisinopril + losartan potassium (NCT01234922)
- 2014-11-20Results posted on the registry: Tulane University, a drug against ACE (NCT01840072)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision